Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
AbbVie today revealed it has bought Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. 15 July 2019
Biotechnology
Australian clinical-stage immuno-oncology company Imugene today announced that it would acquire Vaxinia Pty Ltd via a cash and share deal valued at A$1.619 million ($1.13 billion). 15 July 2019
Biotechnology
British medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Document (FAD), confirming that Skyrizi (risankizumab) is recommended for the treatment of severe psoriasis in adult patients who have failed conventional systemic therapies. 15 July 2019
Biotechnology
The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7 billion in 2017 to $9.2 billion by 2027 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) at a compound annual growth rate (CAGR) of 4.9%. 15 July 2019
Biotechnology
In a deal revealed late Sunday, Galapagos is set to receive upfront payments and an equity investment of more than $5 billion from US biotech major Gilead Sciences. 15 July 2019
Biotechnology
The Düsseldorf Regional Court has found that Praluent (alirocumab) infringes the German part of US biotech firm Amgen’s European patent (EP 2 215 124), relating to rival product Repatha (evolocumab), directed to antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). 15 July 2019
Biotechnology
Maryland, USA-based biotech Altimmune (Nasdaq: ALT) has entered into an agreement to acquire Spitfire Pharma in a cash and stock deal worth up to $93 million. 13 July 2019
Biotechnology
A new report from Boston, USA-based cost-effectiveness watchdog The Institute for Clinical and Economic Review (ICER) will make difficult reading for Duchenne muscular dystrophy (DMD) therapy manufacturers. 12 July 2019
Biotechnology
US biotech major Gilead Sciences has lured high pharma profile Christi Shaw to the company as chief executive of CAR-T cancer therapy specialist Kite. 12 July 2019
Biotechnology
In yet another setback in the quest for Alzheimer’s therapies it was decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer's Prevention Initiative Generation Program. 12 July 2019
Biotechnology
US RNAi therapies specialist Alnylam yesterday announced that Jeff Poulton joined the company on July 11, 2019, and has been appointed executive vice president and chief financial officer (CFO), effective August 13. 12 July 2019
Biotechnology
Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own. 12 July 2019
Biotechnology
US biotech start-up Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences to develop and commercialize ultra-long-acting oral HIV therapies. 10 July 2019
Biotechnology
A bid from France’s Sanofi to market the anti-CD38 therapy isatuximab will be reviewed by the US regulator, with a decision expected by April 30, 2020. 10 July 2019
Biotechnology
San Diego, USA based biotech Mirati Therapeutics has entered a clinical collaboration agreement with Swiss pharma giant Novartis to investigate a combination therapy for solid tumors. 10 July 2019
Biotechnology
Japan’s largest drugmaker Takeda Pharmaceutical announced updated results from its Phase IIIb/IV clinical trial for Adynovate (antihemophilic factor [recombinant], PEGylated) at the 27th Annual International Society on Thrombosis and Hemostasis Congress (ISTH), in Melbourne, Australia. 9 July 2019
Biotechnology
An outsized series B funding round will surely nix rumors that Europe’s largest privately-held biotech is about to list on the Nasdaq. 9 July 2019
Biotechnology
At the annual congress of the International Society on Thrombosis and Hemostasis (ISTH) in Australia, Swiss pharma giant Roche has announced new data for Hemlibra (emicizumab) across multiple pivotal studies in people with hemophilia A. 9 July 2019
Biotechnology
Myelodysplastic syndromes (MDS) are a group of disorders that arise from the inadequate functioning of the bone marrow (the spongy material in bones with stem cells), particularly in blood cell production. 9 July 2019
Biotechnology
RNA interference (RNAi) therapeutics specialist Alnylam Pharmaceuticals has been awarded a positive reimbursement decision in the UK for its novel rare disease therapy Onpattro (patisiran). 8 July 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze